<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875651</url>
  </required_header>
  <id_info>
    <org_study_id>S2357</org_study_id>
    <nct_id>NCT03875651</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Confirm Safety &amp; Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)</brief_title>
  <official_title>A U.S. Post-Approval Study of the SYNERGY 4.50/5.00 mm Everolimus-Eluting Platinum Chromium Coronary Stent System (Evolve 4.5/5.0)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EVOLVE 4.5/5.0 is a prospective, single-arm, multi-center observational (standard of care)
      trial intended to confirm the safety and effectiveness of the SYNERGY 4.50 mm and 5.00 mm
      Coronary Stent System for the treatment of patients with coronary artery disease in large
      vessels (≤ 28 mm in length, by visual estimate, in native coronary arteries &gt; 4.00 mm to
      ≤5.00 mm in diameter, by visual estimate).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF) rate</measure>
    <time_frame>12-months</time_frame>
    <description>12-month Target Lesion Failure (TLF) rate, defined as any ischemia driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Heart Diseases, Coronary</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Cardiovascular Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SYNERGY 4.50 mm and 5.0 mm Coronary Stent System</intervention_name>
    <description>The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients include those with atherosclerotic coronary lesions with vessel diameters
        that can appropriately be treated with 4.50 mm and/or 5.00 mm stents according to the
        commercially approved SYNERGY DFU
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A patient is an acceptable candidate if they require treatment with a 4.50 or 5.00 mm
             SYNERGY stent for the treatment of their disease in accordance with the applicable
             guidelines on PCI, the SYNERGY DFU, and the Declaration of Helsinki.

        Exclusion Criteria:

          -  Planned treatment with a non-SYNERGY stent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C Stoler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Heart and Vascular Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Maurer</last_name>
    <phone>800-876-9960</phone>
    <email>peter.maurer@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne M Carew, MS</last_name>
    <phone>800-876-9960</phone>
    <email>susanne.carew@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glen Henry, MD</last_name>
      <phone>203-785-4114</phone>
      <email>Glen.Henry@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Glen Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clearwater Cardiovascular Consultants</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernardo Stein, MD</last_name>
      <phone>727-467-9393</phone>
      <email>rschbs@cccheart.com</email>
    </contact>
    <investigator>
      <last_name>Bernardo Stein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Yeh, MD</last_name>
      <phone>617-852-3016</phone>
      <email>ryeh@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Yeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Kansas City Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zafir Hawa, MD</last_name>
      <phone>816-221-6750</phone>
      <email>zahawa@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Zafir Hawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Islam Othman, MD</last_name>
      <phone>919-684-2407</phone>
      <email>Islam.othman@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Islam Othman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lindner Center for Research and Education at Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Riley, MD</last_name>
      <email>Robert.Riley@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Robert Riley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Punag Divanji, MD</last_name>
      <phone>832-866-6794</phone>
      <email>divanji@OHSU.edu</email>
    </contact>
    <investigator>
      <last_name>Punag Divanji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne Batchelor, MD</last_name>
      <phone>703-776-3552</phone>
      <email>Wayne.batchelor@inova.org</email>
    </contact>
    <investigator>
      <last_name>Wayne Batchelor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-Eluting Stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy: (http://www.bostonscientific.com/en-US/data-sharing-requests.html).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

